Yu Jin Park

Yu Jin Park

Auto-generated profile, based on publicly available information

Yu Jin Park

Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
YPYu Jin Park
Yu Jin Park
LNLe Phuong Nguyen
Le Phuong Nguyen
NPNaina Pinto
Naina Pinto
MKMi Jeong Kwon
Mi Jeong Kwon
RDRoshan Dsouza
Roshan Dsouza
DYDongeun Yong
Dongeun Yong
Background: Small colony and capnophilic variant cases have been separately reported, but there has been no reports of their simultaneous presence in one isolate. We report a case of Escherichia coli with coexpressed small colony and capnophilic phenotypes causing misidentification in automated biochemical kits and non-reactions in antimicrobial susceptibility test cards. Case presentation: An 86-year-old woman developed urinary tract infection from a strain of Escherichia coli with SCV and capnophilic phenotypes in co-existence. This strain did not grow without the presence of CO2, and therefore proper identification from automated system was not possible. 16 s rRNA sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry was able to identify the bacteria. Conclusion: As these strains do not grow on culture parameters defined by CLSI or on automated systems, proper identification using alternative methods are necessary.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BNBonhyang Na
Bonhyang Na
YPYu Jin Park
Yu Jin Park
JSJieun Seo
Jieun Seo
MPMiri Park
Miri Park
JBJee Yeon Baek
Jee Yeon Baek
JKJi-Man Kang
Ji-Man Kang
Na B, et al. J Korean Med Sci. 2024 Jun;39:e206. https://doi.org/10.3346/jkms.2024.39.e206

4 June 2025 in British Journal of Haematology
Verified
Journal Article
Open access
JKJin Ju Kim
Jin Ju Kim
SKSoon Sung Kwon
Soon Sung Kwon
YCYu Jeong Choi
Yu Jeong Choi
YKYehyun Kang
Yehyun Kang
YPYu Jin Park
Yu Jin Park
JCJong Rak Choi
Jong Rak Choi
Summary: Next‐generation sequencing (NGS) has improved the sensitivity of chimerism assays beyond the limitations of conventional short tandem repeat (STR) methods, enabling the detection of minimal recipient haematopoiesis after haematopoietic stem cell transplantation (HSCT). We evaluated the clinical utility of CASAL, an NGS‐based chimerism assay, in routine practice. We retrospectively analysed 310 patients who underwent STR or CASAL chimerism testing between April 2021 and September 2023. CASAL provided significantly more informative markers than STR (median 18 vs. 6; p < 0.001). Among 260 CASAL samples with paired molecular minimal residual disease (MRD) data, concordance at the 10−4 threshold was ~84%. Low‐level mixed chimerism (2%–5%) detected beyond 1 month post‐HSCT was associated with impending relapse. In survival analyses, patients with both MC and MRD positivity (MC/MRD+) had the highest relapse risk across both platforms. Multivariable Cox regression confirmed MC/MRD+ as an independent predictor of relapse (hazard ratio 5.87, 95% CI: 1.17–29.57). CASAL enables sensitive chimerism monitoring and shows a strong correlation with molecular MRD and clinical outcomes. These findings support its clinical utility for individualized post‐HSCT surveillance, especially in patients lacking leukaemia‐specific molecular targets.

12 February 2026 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
EYEunju Yeom
Eunju Yeom
YPYu Jin Park
Yu Jin Park
SSSaeam Shin
Saeam Shin
SLSeung-Tae Lee
Seung-Tae Lee
MLMi-Kyeong Lee
Mi-Kyeong Lee
JCJong Rak CHOI
Jong Rak CHOI
Eunju Yeom, B.S., Yu Jin Park, M.D., Ph.D., Saeam Shin, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Mi-Kyeong Lee, M.D., Ph.D., Kyoung-Ryul Lee, M.D., Ph.D., Dongju Won, M.D., and Jong Rak Choi, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0414

1 September 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JKJieun Kim
Jieun Kim
DKDong-Moung Kim
Dong-Moung Kim
YPYu Jin Park
Yu Jin Park
SLSeung-Tae Lee
Seung-Tae Lee
HKHyon-Suk Kim
Hyon-Suk Kim
JCJong Rak CHOI
Jong Rak CHOI
Jieun Kim, M.D., Ph,D., Dong-Moung Kim, B.A., Yu Jin Park, M.D., Ph.D., Seung-Tae Lee, M.D., Ph,D., Hyon-Suk Kim, M.D., Ph,D., Myoung Soo Kim, M.D., Ph.D., Beom Seok Kim, M.D., Ph.D., and Jong Rak Choi, M.D., Ph.D.. Ann Lab Med 2021;41:469-78. https://doi.org/10.3343/alm.2021.41.5.469

8 June 2026 in Cells
Verified
Journal Article
Open access
PDF file
NKNamsoo Kim
Namsoo Kim
YPYu Jin Park
Yu Jin Park
YMYoung Kyu Min
Young Kyu Min
SLSeoyoung Lim
Seoyoung Lim
YCYu Jeong Choi
Yu Jeong Choi
SSSaeam Shin
Saeam Shin
Background: Gene fusions play a pivotal role in the pathogenesis and classification of hematologic malignancies. RNA sequencing (RNA-seq) has emerged as a powerful tool for detecting gene fusions; however, many clinical studies have focused on targeted RNA-seq, and optimal parameters for whole transcriptome RNA-seq remain uncertain. Methods: We retrospectively analyzed whole RNA-seq data from 301 patients diagnosed with acute leukemia between October 2022 and May 2025 to characterize the landscape of pathogenic gene fusions. Fusions were identified using the Arriba algorithm, and subsampling analyses were performed on cases with recurrent fusions to determine the minimum sequencing output required for reliable detection. Results: Pathogenic gene fusions were identified in 113 of 301 patients (37.5%). Whole RNA-seq detected fusions that were not identifiable by conventional assays, including UBTF::ATXN7L3, and highlighted frequent fusion events, such as ZNF384 rearrangements. Subsampling analysis demonstrated that a sequencing output ≥ 100 million reads (moderate confidence) or ≥300 million reads (high confidence) was sufficient for 100% detection of recurrent fusions. Conclusions: Whole RNA-seq reliably detects clinically relevant gene fusions in acute leukemia, aligns well with conventional karyotyping results, and surpasses targeted RNA-seq in comprehensiveness. A sequencing output of at least 100 million reads is recommended for clinical fusion detection.